A new computerized tomography classification to evaluate response to Denosumab in giant cell tumors in the extremities.

CONCLUSION: The new CT classification evaluated more accurately the response to Denosumab. Our experience suggests that the requirement for radical bone resection remains high despite the use of Denosumab. LEVEL OF EVIDENCE: Level IV, Therapeutic Study. PMID: 31253385 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31253385?dopt=Abstract

Source: Acta Orthopaedica et Traumatologica Turcica - June 24, 2019 Category: Orthopaedics Authors: Campanacci L, Sambri A, Medellin MR, Cimatti P, Errani C, Donati DM Tags: Acta Orthop Traumatol Turc Source Type: research